RT Journal
A1 Todd S, McGuinness B, Passmore A
T1 DEsigning appropriate clinical trials to assess acei use and cognitive decline in older adults with hypertension
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2010
FD January 11
VO 170
IS 1
SP 107
OP 107
DO 10.1001/archinternmed.2009.463
UL http://dx.doi.org/10.1001/archinternmed.2009.463
AB 
Sink et al1 report that exposure to angiotensin-converting enzyme inhibitors (ACEIs) is not associated with dementia risk or cognitive decline in older hypertensive adults compared with other antihypertensive drugs. Centrally active ACEIs, ie, those that cross the blood-brain barrier (BBB) (animal data), reduced cognitive decline, whereas noncentrally acting ACEIs (BBB impermeable) were associated with greater risk of incident dementia and disability in instrumental activities of daily living.1 These effects were independent of blood pressure regulation and prompted a call for a randomized clinical trial of centrally active ACEIs in the prevention of cognitive decline and dementia.1